Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Nonrandomized, Multi-arm Umbrella Study of Biomarker-Selected Dual-Target CAR-T Cell Modules in Adults With Relapsed or Refractory Hematologic Malignancies
Conditions
Interventions
Autologous CD19/CD22 dual-target CAR-T module
Autologous CD19/CD20 dual-target CAR-T module
+6 more
Locations
1
China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Start Date
March 2, 2026
Primary Completion Date
March 14, 2027
Completion Date
February 17, 2028
Last Updated
April 13, 2026
Lead Sponsor
Beijing Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions